Quick Answer
VYNE Therapeutics Inc. reported R&D Expense of $19.24 million for fiscal year 2025.
VYNE Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.24M | -37.8% |
| 2024 | $30.95M | +89.8% |
| 2023 | $16.31M | -11.3% |
| 2022 | $18.39M | -5.9% |
| 2021 | $19.54M | -55.1% |
| 2020 | $43.53M | -15.0% |
| 2019 | $51.20M | -20.6% |
| 2018 | $64.47M | +122.3% |
| 2017 | $29.01M | +157.7% |
| 2016 | $11.26M | +285.3% |
| 2015 | $2.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $4.88M | -33.2% | -20.3% |
| March 31, 2025 | $6.12M | +65.2% | -40.2% |
| September 30, 2024 | $10.25M | +208.9% | +40.3% |
| June 30, 2024 | $7.31M | +1.0% | +97.0% |
| March 31, 2024 | $3.71M | +35.6% | +11.8% |
| September 30, 2023 | $3.32M | -40.2% | -54.1% |
| June 30, 2023 | $7.23M | +76.1% | +164.6% |
| March 31, 2023 | $2.73M | -38.6% | -50.7% |
- VYNE Therapeutics Inc. showed a decrease of -37.8% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, VYNE Therapeutics Inc.’s r&d expense has grown by 558.6% (from $2.92 million to $19.24 million).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: